KMT2A and acute myeloid leukemia: In KMT2A-rearranged AML, for instance, miR-9a overexpression has been reported to act as an oncogene (23), but, in pediatric patients with t(8;21), overexpression of miR-9a plays a tumor suppressor role (24).